BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Life Sciences Queensland Welcomes Dr. Kym Baker and Dr. Denise Hodge to Board Leadership

Dr. Kym Baker, currently serving as the General Manager of Patheon Biologics at Thermo Fisher Scientific Brisbane Biologics site, brings over 30 years of e...

January 23, 2024 | News

CSIRO Invites Australian SMEs to Join Innovate to Grow Program for Advancing Digital Health and Medical Tech

Australia’s CSIRO is actively seeking startups and small to medium-sized enterprises (SMEs) eager to drive innovation in digital health and medical t...

January 23, 2024 | News

TGA Grants Approval to Australia's Pioneering RSV Vaccine, AREXVY

AREXVY has been approved by the Therapeutic Goods Administration (TGA) for Australians 60 and over to protect against lower airway infection caused by re...

January 19, 2024 | Regulatory

Immunexpress' SeptiCyte RAPID® Gains TGA Clearance in Australia

Immunexpress, a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced that SeptiCyte® RAPID has rec...

January 17, 2024 | News

Smith+Nephew Report Urges Overhaul of Musculoskeletal Injury Care and Reimbursement in Australia

The Economist Impact - Musculoskeletal Injuries in Australia Report outlines the growing number of meniscal injury (MI) and rotator cuff (RC) injur...

January 15, 2024 | News

Australia Achieves Positive Results in Phase Ib Study for Androgenic Alopecia Treatment

This study is led by Professor Rodney Sinclair and included 12 male and 4 female patients in Australia with androgenic alopecia (AGA). ...

January 15, 2024 | News

GC Cell Initiates Phase 1 Trials for AB-201 Cancer Treatment with Lunit AI Platform

GC Cell, a fully integrated cell therapy pioneer, is proud to announce the approval from both the Australian Human Research Ethics Committee (HREC) a...

January 09, 2024 | News

Australia's GPN Vaccines Reports Positive Phase 1 Data for Gamma-PN Trial

In this double-blind, randomised study with placebo and active controls, 120 participants received either two doses of 50, 250 or 1000 micrograms of Gamma-...

January 04, 2024 | News

Asieris' APL-2301 Approved for Phase I Trials in Australia for Acinetobacter baumannii Infection

The planned clinical trial in Australia will be the first-in-human Phase I trial for APL-2301. It aims to evaluate the safety, tolerability, phar...

December 26, 2023 | News

Biocon Biologics Successfully Integrates Acquired Biosimilars Business Across 120 Countries

Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully conc...

December 19, 2023 | News

Australian Neuren Phase 2 Trial Reveals Significant Improvements in Phelan-McDermid Syndrome

Highlights: Significant improvement was assessed by both clinicians and caregivers across multiple efficacy measures Improvements were con...

December 19, 2023 | News

Advancing Lung Cancer Treatment: Insights from Professor Benjamin Solomon on the ALINA Study and the Future of ALK-Positive NSCLC

In an exclusive BioPharma APAC interview, Professor Benjamin Solomon, a distinguished Medical Oncologist at the Peter MacCallum Cancer Centre, Australia, a...

December 18, 2023 | News

MGI Australia Introduces Innovative CEC with DCS Lab Products for Advanced DNA, Cell, and Spatial-omics Technology

MGI Australia, a subsidiary of MGI Tech Co. Ltd. (MGI), a global leader in life science technology, is delighted to announce a substantial expans...

December 15, 2023 | News

Atmo Biosciences achieves patient recruitment target for dysmotility pivotal clinical study

Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome fu...

December 14, 2023 | News

Stay Connected